Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Details

Serval ID
serval:BIB_4DAFF0202FDC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Journal
Nature reviews. Clinical oncology
Author(s)
Fukumura D., Kloepper J., Amoozgar Z., Duda D.G., Jain R.K.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Publication state
Published
Issued date
05/2018
Peer-reviewed
Oui
Volume
15
Number
5
Pages
325-340
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently, however, the majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumours and facilitate immune evasion. These abnormalities stem from elevated levels of proangiogenic factors, such as VEGF and angiopoietin 2 (ANG2); judicious use of drugs targeting these molecules can improve therapeutic responsiveness, partially owing to normalization of the abnormal tumour vasculature that can, in turn, increase the infiltration of immune effector cells into tumours and convert the intrinsically immunosuppressive tumour microenvironment (TME) to an immunosupportive one. Immunotherapy relies on the accumulation and activity of immune effector cells within the TME, and immune responses and vascular normalization seem to be reciprocally regulated. Thus, combining antiangiogenic therapies and immunotherapies might increase the effectiveness of immunotherapy and diminish the risk of immune-related adverse effects. In this Perspective, we outline the roles of VEGF and ANG2 in tumour immune evasion and progression, and discuss the evidence indicating that antiangiogenic agents can normalize the TME. We also suggest ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes, and highlight avenues of future research.
Keywords
Angiogenesis Inhibitors/therapeutic use, Humans, Immunotherapy/trends, Neoplasms/drug therapy, Neoplasms/immunology, Neovascularization, Pathologic/drug therapy, Neovascularization, Pathologic/immunology, Tumor Microenvironment/drug effects, Tumor Microenvironment/immunology, Vascular Endothelial Growth Factor A/immunology, Vascular Endothelial Growth Factor A/therapeutic use, Vesicular Transport Proteins/immunology, Vesicular Transport Proteins/therapeutic use
Pubmed
Web of science
Create date
10/03/2018 9:21
Last modification date
20/08/2019 14:02
Usage data